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adult bronchiectasis patients
Paul Purcell1, Hannah Jary2, Audrey Perry3,4, John D Perry3,4, Christopher J Stewart1, Andrew Nelson1,
Clare Lanyon1, Darren L Smith1, Stephen P Cummings1* and Anthony De Soyza2Abstract
Background: Chronic airway infection contributes to the underlying pathogenesis of non-cystic fibrosis bronchiectasis
(NCFBr). In contrast to other chronic airway infections, associated with COPD and CF bronchiectasis, where
polymicrobial communities have been implicated in lung damage due to the vicious circle of recurrent bacterial
infections and inflammation, there is sparse information on the composition of bacterial communities in NCFBr. Seventy
consecutive patients were recruited from an outpatient adult NCFBr clinic. Bacterial communities in sputum samples
were analysed by culture and pyrosequencing approaches. Bacterial sequences were analysed using partial least square
discrimination analyses to investigate trends in community composition and identify those taxa that contribute most
to community variation.
Results: The lower airway in NCFBr is dominated by three bacterial taxa Pasteurellaceae, Streptococcaceae and
Pseudomonadaceae. Moreover, the bacterial community is much more diverse than indicated by culture and contains
significant numbers of other genera including anaerobic Prevotellaceae, Veillonellaceae and Actinomycetaceae. We found
particular taxa are correlated with different clinical states, 27 taxa were associated with acute exacerbations, whereas
11 taxa correlated with stable clinical states. We were unable to demonstrate a significant effect of antibiotic
therapy, gender, or lung function on the diversity of the bacterial community. However, presence of clinically
significant culturable taxa; particularly Pseudomonas aeruginosa and Haemophilus influenzae correlated with a
significant change in the diversity of the bacterial community in the lung.
Conclusions: We have demonstrated that acute exacerbations, the frequency of exacerbation and episodes of
clinical stability are correlated, in some patients, with a significantly different bacterial community structure, that
are associated with a presence of particular taxa in the NCFBr lung. Moreover, there appears to be an inverse
relationship between the abundance of P. aeruginosa and that of of H. influenzae within the NCFBr lung
bacterial community. This interaction requires further exploration.
Keywords: Bronchiectasis, Bacterial colonisation, SputumBackground
Bronchiectasis is a significant cause of chronic respiratory
disease resulting in irreversible abnormally dilated bronchi
associated with chronic inflammation, chronic cough and
sputum production [1]. It can be caused by physical ob-
struction or post infectious damage, genetic defects (as
observed in cystic fibrosis), abnormal host defence or
autoimmune disease but in many cases bronchiectasis
is idiopathic [2]. In this study we have focussed on the* Correspondence: Stephen.cummings@northumbria.ac.uk
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unless otherwise stated.examination of a cohort of patients that presented with
non-CF bronchiectasis (NCFBr).
Chronic airway infection contributes to the underlying
pathogenesis of the disease, with progressive lung dam-
age resulting from recurrent bacterial infections and in-
flammatory responses [3]. The most commonly cultured
pathogens associated with sputum of NCFBr are Hae-
mophilus influenzae and Pseudomonas aeruginosa with
many isolated strains showing significant antibiotic re-
sistance [1,4]. In prior studies, individuals that were
culture-negative for bacterial pathogens showed the
mildest disease, whereas, those with P. aeruginosa had
the most severe bronchiectasis [5]. Consequently, theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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identified as a marker of bronchiectasis severity, although
it remains unclear whether this is causal or associated with
accelerated lung function decline [6].
Frequent exacerbations experienced by bronchiectasis
patients may contribute to the progressive decline of
lung function [7], though both the aetiology and patho-
physiology of exacerbations remains poorly understood.
Exacerbations are frequently managed with antibiotics,
however, viral infections may also be significant in many
cases but their role requires clarification [1].
The aim of this study was to investigate the airway
microbiota in NCFBr and characterise its diversity and
structure. We aimed to test the hypotheses that bacterial
community differences reflect the exacerbation history
of the patient, that the presence or absence of culturable
pathogens sculpted the structure of the airway micro-
biome and that the bacterial community would show
significant change in response to the interventions used
to manage patient outcomes.
Results
Patient cohort
Patient baseline data are summarised in Table 1. The
study population consisted of 25 males and 45 females.
The self-reported exacerbation rates in the preceding
12 months were available for 61 of the 70 patients.
Thirty-eight patients were identified as frequent exacerba-
tors with more than 3 exacerbations in a 12 month period.
At the time of sample collection 20 patients reportedTable 1 Patient data for the cohort
Demographic data All patients
(n = 70)
Non-exacerbated
(n = 50)
Exacerbated
(n = 20)
Age (yr) 61.6 ± 13 61.2 ± 13.4 62.5 ± 13
Female (%) 64.3 60 75
FEV (L) 1.46 1.45 1.54
Males 1.78a 1.80a 1.77a
Females 1.26b 1.20b 1.45b
FEV1% predicted 57.9 55.2 64.9
Frequent exacerbation
(%)* (n = 61)
61.7 56 45
Culture negative (%) 38.6 22 40
H. influenzae
colonisation (%)
21.4 12 45
P. aeruginosa
colonisation (%)
32.8 40 15
Recent Antibiotics (%)+ 24.3 22 30
*Frequency of exacerbation data (available for 61 patients). Frequent
exacerbators defined as >3 episodes per annum. + Indicates treatment within
the last month with antibiotics other than maintenance colomycin or
azithromycin. Values followed by different letters are significantly different
(p < 0.05). When corrected for sex and height the FEV1% predicted were
similar between the 2 genders.symptoms consistent with exacerbation (Additional file 1:
Table S1).
Microbial culture
Sputa from 51 patients (73%) were culture positive for
pathogenic microorganisms, the remainder either yielded
no bacteria or non-pathogenic mixed oral flora as deter-
mined by the standard culture protocol used in the clinic
(Additional file 1: Table S1). The most common organisms
were P. aeruginosa found in 33% and H. influenzae in 21%
of patients respectively. There were no instances of both
P. aeruginosa and H. influenzae being found within a
single sputum sample. Patient records showed that 24
individuals had P. aeruginosa isolated from all previous
sputum samples referred for culture; these patients were
regarded as persistently colonised. There were 17 patients
regarded as intermittently colonised, with P. aeruginosa
isolated from at least one but not all sputa samples and 29
patients were culture negative. The majority (71%) of fre-
quent exacerbators (n = 38) were culture positive for lung
pathogens. Of these individuals, 50% were colonised with
P. aeruginosa and 10.5% with H. influenzae.
The relationship between culture status and lung
function
Lung function, was determined by forced expiratory vol-
ume in one second (FEV1% predicted). In patients har-
bouring H. influenzae or where culturable pathogens were
absent FEV1% predicted was 64.5 and 64.9 respectively,
these values were significantly higher (P = 0.0002 and
P = 0.0001 respectively) in comparison with individuals
whose sputum was culture positive for P. aeruginosa
(FEV1% predicted = 48.5). Lung function was signifi-
cantly lower (P < 0.001) in patients persistently colonised
with P. aeruginosa (FEV1% predicted = 40.6) compared
those ‘never’ or intermittently colonised by this pathogen
(FEV1% predicted 59.7 and 69.8 respectively). In con-
trast, those never colonised and those intermittently
colonised did not have significantly different FEV1%
predicted values. Patients who frequently exacerbated
(FEV1% predicted = 58.8) and those that did not (FEV1%
predicted = 59.3) had no significant difference in lung
function.
The bacterial community structure derived by 16S rRNA
gene amplicon pyrosequencing
Pyrosequencing data (Additional file 2: Figure S1) re-
vealed that the sputum samples contained on average 50
individual families (range 13–144). Bacterial community
diversity was not significantly different between genders.
Community diversity was not significantly correlated with
FEV1% predicted (P = 0.28).
There were three dominant families in the sputa, the
first was Pseudomonadaceae, where a single operational
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for this taxa. Comparison with culture data and analyses
of the sequence data to putative species level (Additional
file 3: Table S2) indicated this OTU was P. aeruginosa.
The second major taxa was Pasteurellaceae, 84% of reads
for this family belonged to a single OTU that culture data
and sequence analyses to putative species level indicated
was H. influenzae. A further 9% of the remaining reads
belonged to a second OTU, found in only one patient
(BX16), from which only H. parainfluenzae had been
cultured. The third abundant taxa belonged to Strepto-
coccaceae, where two OTUs contributed 88% of all reads
for this group.
Culture analyses of the sputum samples (Table 1) indi-
cated that 27% of the patients were negative for organisms
regarded as of concern clinically. However, sequence data
showed that these individuals had significantly greater
numbers of taxa present than culture-positive patients
(average 63 versus 46 taxa, P = 0.011). The predominant
organisms in culture negative samples were Streptococca-
ceae, representing on average 48% of the total community
in these samples which are likely to represent those
streptococci that are not detected by the standard culture
techniques used to analyse the sputum. Pseudomonada-
ceae was found to contribute to the community compos-
ition, although not detectable by culture, however, in
exacerbating samples it contributed, on average 0.2%
whereas, in stable samples it contributed 13% to the
total community composition.Figure 1 Canonical correspondence analysis of (A) total cohort showi
had culturable P. aeruginosa (P = 0.002) and culturable H. influenzae (
assemblies, (B) Frequent exacerbators also showing that samples t
(P = 0.002) and culturable H. influenzae (P = 0.002) were associated wi
indicated by ▲, are; Culture positive sputum; H.i, H. influenzae detected by
analysed; the presence of an exacerbation at time of sampling; 12 month h
current azithromycin treatment; current nebulised colistin treatment; gende
to significantly affect the community structure and for clarity are not showThe role of environmental variables in driving bacterial
community structure
In order to investigate impact of patient specific and
clinical variable on the bacterial community structures
the bacterial profiles from the patient cohort were sub-
jected to ordination analysis (CCA) and permutation
testing. Analyses were performed on the bacterial com-
munity resolved to family level then repeated with puta-
tive species level resolution. These analyses constrained
the community profile variance with 13 measured vari-
ables (Culture positive sputum; H. influenzae detected
by culture; P. aeruginosa detected by culture; the pres-
ence of an exacerbation at time of sampling; 12 month
history of persistent; intermittent or absence of culturable
P. aeruginosa, antibiotic treatment in previous month;
current azithromycin treatment; current nebulised colistin
treatment; gender, FEV1% predicted and age) derived from
patient records. For the family level analyses, these vari-
ables explained 64.4% of the total variance in the data but
only three were significantly associated with the variance
in bacterial community structure. These were culture
positive sputum (P = 0.016); the presence of culturable
H. influenzae (P = 0.002); and culturable P. aeruginosa
(P = 0.002) (Figure 1A).
These analyses were repeated for the frequent exacer-
bator cohort all of whom had received antibiotic inter-
vention in the preceding 12 months. These variables
contributed to 62% of the variance in the community
structure but significant associations between the microbialng that sputum samples that were culture positive (P = 0.016);
P = 0.002) were associated with distinct bacterial community
hat were culture positive (P = 0.05); had culturable P. aeruginosa
th distinct bacterial community assemblies. Discrete variables,
culture and P.a, P. aeruginosa detected by culture. Other variables
istory of persistent; intermittent or absence of culturable P. aeruginosa,
r, FEV1% predicted; frequent exacerbation and age. None were found
n. Percentage values show variance within data explained by that axis.
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tum (P = 0.05), the isolation of H. influenzae (P = 0.002)
and the isolation of P. aeruginosa (P = 0.002) (Figure 1B).
Repeating these analyses at putative species level reso-
lution found the same result, with only these three vari-
ables showing significant associations with the bacterial
community structure.
The presence of culturable H. influenzae and cultur-
able P. aeruginosa exerting significant effects on com-
munity structure was supported by examination of the
read numbers of these taxa in the pyrosequencing ana-
lysis. When one species was present (with one exception,
patient 63), then the other species did not contribute
more than 1.5% to the total bacterial community profile
(Additional file 2: Figure S1).
The other variables analysed were the presence of an
exacerbation at time of sampling; 12 month history of
persistent; intermittent or absence of culturable P. aerugi-
nosa; current azithromycin treatment; current nebulised
colistin treatment; gender, FEV1% predicted; antibiotic
treatment in previous month and age. None were
found to significantly affect the community structure
in either the total or frequently exacerbating cohorts.
Of particular interest were 25 patients that had not re-
ceived antibiotics for one month prior to sample col-
lection. Ordination analyses (Figure 1A) showed that
these individuals did not have significantly different bac-
terial communities to those who were receiving antibiotic
therapy.Figure 2 Partial least squares discriminant analysis (PLS-DA) loading p
determined by 454 sequence analysis of the microbiota of sputum fr
from patients reporting a current exacerbation (blue circle). PLS1 (R2X
Q2 = 0.0601) are given. The solid ellipse indicates Hotellings T2 range, at 95%
contained within the dashed ellipse, and including BX6 are deemed to be
is dissimilar to the stable and a small proportion of exacerbating patients. SBacterial community structure and clinical status
For partial least squares discriminant analysis (PLS-DA),
samples were classified according to exacerbation status
with group 1 (n = 50) being stable and group 2 (n = 20)
exacerbating at time of sampling. The model made no
further assumptions about each patient group. Analysis
of the scatter plot of scores (Figure 2), demonstrated
that 8 individuals from the exacerbating group (40%)
had bacterial community structures that were distinct
from those of the remaining patients. Within the 20 in-
dividuals sampled during an exacerbation, 12 patients
exhibited a community composition that was similar to
22 patients who were stable at time of sampling in terms
of projection in the XY space. The remaining 28 stable
patients had a community composition that was distinct
from the remaining 8 exacerbation patients (Figure 2).
Eleven bacterial taxa, including members of Pseudo-
monas, Neisseria and Enterobacteriales were associated
with the stable clinical state. Conversely, 27 taxa were
positively correlated with exacerbation, including Bur-
kholderiales, Pasteurellaceae, Streptococcaceae, Xantho-
monadaceae, Prevotellaceae and Veillonellaceae as well
as other taxa not regarded as pathogens (Propionibacter-
ium, Flavobacteriales and Actinobacteria) (Figure 3).
Bacterial community analysis of the lung microbiota from
frequently exacerbating patients
Analytical models were extended to explore any differences
in prior exacerbation history. From the cohort, 59 patientslot based on the relative abundance of bacterial taxa
om patients reporting current stability (green circle) and sputum
= 0.169, R2Y = 0.232, Q2 = 0.0287) and PLS 2 (R2X = 0.107, R2Y = 0.124,
confidence. Patient samples derived from current exacerbators
the major outliers, having a microbial community composition which
ome sample labels have been removed for ease of interpretation.
Figure 3 Partial least squares discriminant analysis (PLS-DA) loading plot showing the contributing microbial community members
towards the separation of the PLS-DA scores between patients reporting current stability (▲) and sputum from patients reporting a
current exacerbation (▼). PLS1 (R2X = 0.169, R2Y = 0.232, Q2 = 0.0287) and PLS 2 (R2X = 0.107, R2Y = 0.124, Q2 = 0.0601) are given. Taxa deemed
clinically relevant (based on those screened during standard culture) are highlighted in blue. Some sample labels have been removed for ease
of interpretation.
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defined as frequently exacerbating (M1, n = 38 having
more than 3 exacerbation events per annum) or stable
(M2, n = 23, ≤3 event pa). Analysis of the model showed
that 22 patients from M1 and 17 from M2 had bacterial
profiles that were similar, despite exacerbation history
(indicated with an ellipse, Figure 4). The remaining
20 patient samples, however, could be stratified between
stable and frequent exacerbation states (Figure 4). Further
analysis of the overall bacterial community structure
between frequent exacerbating (M1) and stable (M2)
patients revealed Moraxellaceae, Xanthomonadaceae,
Rhodobacteraceae and Staphylococcaceae were positively
associated with frequent exacerbation and Campylobac-
teraceae, Carnobacteriaceae, Corynebacteriaceae, Micro-
coccaceae, Neisseriaceae and Nocardiaceae were positively
associated with stability (Figure 5). Pasteurellaceae, Strep-
tococcaceae, Pseudomonadaceae that were associated with
stable patients (Figure 3), were not explanatory factors in
this model (covariance between p1 and p2 was close to 0).
Discussion
Microbial culture techniques have proven highly effective
in identifying pathogens and managing acute infections.
However, current sequencing approaches add doubts about
the utility of these techniques in explaining the clinical par-
adigms in chronic polymicrobial infections [8]. Data on the
polymicrobial communities in the lower airway of non CF
Bronchiectasis using 16S rRNA gene amplicon sequencing
is currently sparse. However, we identified, in commonwith previous studies, that in this NCFBr patient cohort,
three taxa, Streptococcaceae, Pseudomonadaceae and Pas-
turellaceae were dominant (Additional file 2: Figure S1)
[2,9,10]. We also showed that similar to CF bronchiectasis,
the bacterial community was much more diverse than re-
vealed by culture [2,11]. Contamination of the samples by
oral flora is likely to occur during the production of the
sputum. Although samples were washed [12] to minimise
their impact, it is inevitable that oral bacteria are present
in the samples and affect the bacterial communities found.
The relationship between bacterial diversity, patient fac-
tors and disease progression in NCFBr remains to be
determined. Rogers et al. [11] demonstrated a positive
correlation between microbial diversity of the NCFBr
lung with gender and lung function. In contrast, we
and other studies [10] found no significant correlation
between microbiome diversity and lung function, nor
does our data support a significant difference in bac-
terial diversity between genders or gender significantly af-
fecting the bacterial community structure in the NCFBr
lung (Figure 1).
As previously reported [4] we found that 27% of the
sputum samples tested were culture negative for recog-
nised pathogens, although pyrosequencing demonstrated
all had diverse bacterial communities. These included the
anaerobic genera Prevotellaceae, Streptococcaceae, Veillo-
nellaceae and Actinomycetaceae (Figure S1) that have
been identified in other NCFBr microbial communities
[9,11] as well as the bacterial communities found in CF
and COPD lungs [13,14]. The role of these taxa remains
Figure 4 Partial least squares discriminant analysis (PLS-DA) loading plot based on the relative abundance of bacterial taxa
determined by 454 sequence analysis of the microbiota of sputum from patients with greater than 3 exacerbation event per annum
(green circle) and sputum from patients with 3 or fewer exacerbation events per annum (blue circle). PLS1 (R2X = 0.0701, R2Y = 0.232,
Q2 = 0.0467) and PLS 2 (R2X = 0.0477, R2Y = 0.124, Q2 = 0.0601) are given. The solid ellipse indicates Hotellings T2 range, at 95% confidence. Patient
samples falling outside of the ellipse are deemed to be the major outliers. Some sample labels have been removed for ease of interpretation.
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ber of them were correlated with exacerbations (Figure 3) or
frequently exacerbating patients (Figure 5). A recent study
has identified a relationship between neutrophilic air-
way inflammation and the total bacterial communityFigure 5 Partial least squares discriminant analysis (PLS-DA) loading p
towards the separation of the PLS-DA scores between patients are fre
sputum from patients who are stable (≤3 exacerbation events per an
during standard culture) are highlighted in blue. Some sample labels havesuggesting a role for the whole lung microbiota in dis-
ease progression [15].
Our data indicates that the presence of culturable path-
ogens, particularly P. aeruginosa and H. influenzae are
significant factors affecting bacterial communities inlot showing the contributing microbial community members
quent exacerbators (>3 exacerbation events per annum) and
num). Taxa deemed clinically relevant (based on those screened
been removed for ease of interpretation.
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to the concept of core and satellite taxa in the chronic-
ally infected lung [16]. Core taxa are regarded as well
adapted to the lung environment and able to persist,
whereas satellite taxa are less well adapted and transient. If
P. aeruginosa, H. influenzae and streptococci (Additional
file 2: Figure S1) are core taxa, they may shape the com-
munity structure within a particular lung microbiome
(Figure 1). For example, sputum samples from patients
where P. aeruginosa had been persistently or intermit-
tently cultured in the past contained significantly fewer
taxa (44 versus 58, P = 0.012). This finding has previ-
ously been reported in CF studies where persistent col-
onisation was associated with mucoid and genetically
adapted strains of P. aeruginosa [17]. There has been
evidence to support the stratification of patients with
NCFBr on the basis of P. aeruginosa culture with those
chronically infected showing significantly lower lung
function or poorer outcomes, including reduced bacterial
diversity than those intermittently or never colonised pa-
tients [5-7,18,19]. Similarly, we found a significant re-
duction in FEV1% predicted (P < 0.001) between those
patients persistently versus never colonised with P. aerugi-
nosa. However, there was no significant link between low
community diversity and FEV1% predicted.
As Pseudomonas was associated with a less diverse poly-
microbial community we assessed its effect on the most
prevalent pathogen in NCFBr. We observed that with cul-
ture and pyrosequencing data, H. influenzae, and P. aerugi-
nosa were inversely related in sputum samples (Additional
file 2: Figure S1). The pyrosequencing data showed when
one is present (with one exception, patient 63), then the
other did not contribute more than 1.5% to the total bac-
terial community profile (Additional file 2: Figure S1). In
culture, H. influenzae was never co-isolated with P. aerugi-
nosa (Table 1). This inverse relationship has been reported
by others, for example, paediatric CF bronchiectasis pa-
tients showed a similar relationship between P. aeruginosa
and H. influenzae in both culture and pyrosequencing ana-
lyses of microbial communities [10]. The implication is
that both taxa cannot be regarded as part of a single ‘core’
microbiome. It remains unclear whether the inhibition of
H. influenzae reflects antibiotic pressures, the arrival of
P. aeruginosa, or a combination of these factors [19]. It
could also reflect patient specific effects selecting for
and leading to divergence in the airway communities.
Such patient specific effects have been observed in other
studies [20] but the underlying reasons are yet to be ex-
plained. We found H. influenzae was, however, present in
patients with long term and repeated antibiotic therapy
(data not shown). P. aeruginosa has been shown to inhibit
the growth of H. influenzae in vitro [21] which suggests
our observations may reflect competition between these
two major pathogens in the human lung [22].We modelled whether patients could be stratified on
the basis of their microbiome, in particular, to determine
whether patients undergoing a current exacerbation at
sampling or those who were frequent exacerbators had a
characteristic microbial community compared to stable
patients or those who were infrequent exacerbators. Com-
paring acute exacerbations versus stable patients’ the bac-
terial community profiles indicated three groupings, a
small exacerbating group, a group containing both stable
and exacerbating patients and a third group of stable pa-
tients (Figure 2). We found particular taxa are correlated
with different clinical states for example, 27 taxa including
Pasteurellaceae, Streptococcaceae, Xanthomonadaceae,
Burkholderiales, Prevotellaceae and Veillonellaceae were
associated with acute exacerbations, whereas 11 taxa in-
cluding Pseudomonas species correlated with stable clin-
ical states (Figure 3). These observations, suggest that the
bacterial community in the lung of exacerbating bronchi-
ectasis patients has a more dynamic community compos-
ition than that seen in stable patients. It may be that
the three groups identified based on community pro-
files are transient and individuals move in and out of
them depending upon frequency of exacerbation, anti-
biotic treatment or other factors. Culture based studies
of COPD suggest strain emergence is associated with
exacerbations [23]. Although no patients were culture
positive for Burkholderia spp., the presence of 1% of
amplicons belonging to Burkholderiales, with one OTU
accounting for 94% of the reads which was present, albeit
in low numbers in 27% of the cohort, is notable as these
organisms have not previously been considered pathogens
in NCFBr.
We hypothesised that those individuals who frequently
exacerbate would have significantly different bacterial com-
munity compositions and diversity compared to clinically
stable patients. Soft-class modelling did not give a definitive
answer, 39 profiles of both frequent exacerbators and stable
patients were indistinguishable in the model, however, it
did stratify a small group of 6 stable patient’s bacterial com-
munities from those of a distinct group of 14 frequently ex-
acerbating individuals (Figure 4). These profiles were not
significantly different in terms of diversity or evenness (data
not shown), but indicated certain taxa, particularly,
Rhodobacteraceae, Xanthomonadaceae Staphylococca-
ceae and Moraxellaceae were associated with frequent
exacerbations. The latter three taxa include established
pathogens in acute exacerbations [24]. Here they are
also implicated in increasing the frequency of exacer-
bation events. In contrast, the significance of taxa such
as Rhodobacteraceae that are not routinely identified
by standard culture is unknown. It is possible that they
may be pathogenic, enhance the pathogenicity of clin-
ically significant taxa or contribute to airway inflam-
mation and decline in lung function [25,26].
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cohort was consecutively recruited from an NCFBr out-
patients clinic, hence, the administration of varying anti-
biotic regimens to individuals within the cohort may be
a confounding factor. We identified 25 patients that had
not received antibiotics for one month prior to sample
collection. Ordination analyses (Figure 1) showed that
these individuals did not have significantly different bac-
terial communities to those who were receiving anti-
biotic therapy. Our data suggests that antibiotics do not
significantly perturb bacterial communities in the lower
airway, however, transient impacts on abundance and di-
versity have been observed in longitudinal studies looking
at microbial communities in sputum from CF patients
[15,20]. The clinical benefit of antibiotic therapy in chronic
lung infection may, therefore, be due to the reduction in
bacterial load present [27]. A longitudinal study is required
to confirm if a similar transient response is observed in
NCFBr microbial communities. Other limitations are that
in this cross sectional study we cannot gauge the level of
temporal change within the lung microbiome, which if sig-
nificant, may confound analyses showing differences in
communities between individual patients. However, exam-
ining DGGE analyses of longitudinal samples from 35 indi-
viduals within this cohort (unpublished data) and other
data using pyrosequencing approaches [10] shows that
bacterial communities within an individual are relatively
stable through time. A third issue, is that pyrosequencing
relies on relatively short amplicons that lack sufficient
resolution to confidently assign taxa to species, certainly
not to strain-level. In many cases there is no independent
culture data to support the metagenomic analyses and
clinically significant strain differences are undetectable
[24]. Finally, although exacerbations at time of sampling
were clinically defined, and those in the preceding
12 months were determined where possible from pa-
tient records, some of the exacerbations episodes were
self-reported by patients and as a result may not reflect
the clinical definition used at time of sampling.
Conclusions
In summary, we have demonstrated that the microbial
community of the lower airway in NCFBr is dominated
by three bacterial taxa Pasteurellaceae, Streptococcaceae
and Pseudomonadaceae. We also show that the airway
microbial community is much more diverse than indi-
cated by culture and contains significant numbers of
other genera including anaerobic Prevotellaceae, Veillo-
nellaceae and Actinomycetaceae. We were unable to dem-
onstrate a significant effect of antibiotic therapy, gender,
or lung function on the diversity of the bacterial commu-
nity. We did find presence of clinically significant cultur-
able taxa; particularly P. aeruginosa and H. influenzae
exerted a significant effect on the diversity of the bacterialcommunity in the lung. Moreover, a high abundance of
one of these pathogens is consistent with, but does not
prove its causality in limiting the presence of the other
taxa within the NCFBr lung bacterial community. This
interaction requires further exploration. We also demon-
strated that both acute exacerbations, the frequency of
exacerbation and episodes of clinical stability cause, in
some patients, a significantly different bacterial commu-
nity structure, that are associated with a presence of par-
ticular taxa in the NCFBr lung.
Methods
Ethics statement
Ethical approval for the study was by the National Re-
search Ethics committee (ref 12/NE/0248). Participants
provided written informed consent prior to entry in the
study.
Patient cohort
The inclusion criteria were adult out-patients attending
a specialist bronchiectasis clinic in North East (NE) Eng-
land, U.K. with a clinical diagnosis of NCFBr confirmed
by High Resolution CT scanning. All non-CF aetiologies
were included with idiopathic and post infectious aetiol-
ogies predominant; a minority were immunodeficiency re-
lated, rheumatoid arthritis or COPD related (Additional
file 1: Table S1). Exclusion criteria were radiological evi-
dence of bronchiectasis without sputum production or
entry into any other clinical trial. Aetiological designation
was based upon a published protocol [2]. Cystic fibrosis
genotyping and/or sweat testing was undertaken as per
national guidelines [28]. Recruitment was on an unse-
lected consecutive basis. Information on bronchiectasis
aetiology, patient gender, age, 12 month previous history
of exacerbations, forced expiratory volume in one sec-
ond (FEV1), and maintenance chronic antibiotic ther-
apy (Azithromycin 250 mg once daily, thrice weekly)
or inhaled antibiotic therapy was collected by review-
ing patient case notes (Additional file 1: Table S1). For
current clinical status at time of sampling an exacerba-
tion was defined as the presence of increased cough,
malaise with increased sputum volume and purulence
requiring antibiotic treatment. Frequent exacerbators
were defined as those patients who reported more than
3 episodes over the preceding 12 months [28]. 25 patients
recruited were found to have received neither antibiotics
for acute treatment of an exacerbation or azithromycin for
one month prior to sampling. Patients were classed as
current exacerbators if they reported an increase beyond
their baseline level of symptoms that were consistent with
an exacerbation as defined by national Bronchiectasis
guidelines [28]. Lung function was determined by forced
expiratory volume in one second (FEV1% predicted) in all
patients according to national standards.
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Spontaneously expectorated sputum samples were col-
lected from consecutive outpatients within a cohort of
adult NCFBr patients. The samples were washed with
phosphate-buffered saline to remove any contamination
from oral flora [12]. Each sample was homogenised with
Sputasol (Oxoid) and divided into two aliquots, one for
subsequent DNA extraction and one for immediate cul-
ture, performed in accordance with national standard
methods in an accredited UK clinical laboratory. Briefly,
10 μL aliquots of homogenised sputum were cultured
onto Columbia blood agar and Chocolate agar plus baci-
tracin. The sample was subsequently diluted 1/100 in
sterile saline (0.85%) and 10 μL of this was cultured onto
chocolate agar and incubated in air plus 5% carbon diox-
ide (37°C, 48 h). Isolates were identified by matrix assisted
laser desorption ionisation time-of-flight (MALDI-TOF)
mass spectrometry (Bruker Daltonics) and, where neces-
sary, appropriate API kits (bioMérieux) [29]. Information,
from up to 10 years previously on prior P. aeruginosa sta-
tus, was collected (Additional file 1: Table S1). Persistent
infection was defined as isolation ofa taxa from previous
sputum samples with a minimum requirement of having
been cultured on two or more occasions [2] based upon
current and prior sputa culture data. Intermittent colon-
isation was defined as isolation of taxa from a patient’s
sputa preceded or followed by sputa that was culture
negative. DNA was extracted from 0.5 ml of each sputum
sample using the MoBio Ultraclean Microbial DNA isola-
tion kit (MoBio, CA, USA) according to the manufac-
turer’s protocol. A negative control where template DNA
was replaced with sterile distilled water was prepared with
the same reagents. Extracted DNA was quantified with a
NanoDrop 1000 Spectrophotometer (Thermo Scientific).
454 Pyrosequencing
From standardised concentrations of template DNA a
portion of 16S rRNA gene (position 341 to 907; Escheri-
chia coli numbering) was amplified using the primer set
341 F and 907R [30]. DNA sequencing was performed
using the 454 GS FLX Titanium Sequencing System
(Roche, IN, USA) by the Research and Testing Laboratory
(RTL, TX, USA) using previously described methods [31].
The raw sequencing reads were quality filtered in QIIME
1.6.0 [32] using the split-library.py script. Remaining high
quality sequences were clustered into operational taxo-
nomic units (OTUs) at 97% similarity using UCLUST [33].
Representative sequences for each OTU were aligned using
PyNAST [34] and taxonomic identities were assigned using
RDP-classifier (version 2.2) [35] with 50% as confidence
value threshold. Detection of potentially chimeric se-
quences was performed using ChimeraSlayer [36] and
chimeric sequences were removed from downstream
analysis prior to tree building using FastTree [37].Analyses were run to the family level of taxonomic
resolution and also to species level (Additional file 3:
Table S2). However, species level identification can only be
regarded as putative given the relatively short fragment of
the 16S rRNA gene sequenced. Sequences were deposited
in MG-RAST under the accession numbers 4534396.3-
4534463.3.
Polymicrobial community and statistical analyses
Clinical parameters were tested using Students t-tests
and probability (P) values <0.05 deemed to be statisti-
cally significant. Distribution of data was tested using
Shapiro-Wilk test (α =0.05). Community sequence data
were first analysed by de-trended correspondence ana-
lysis (DCA). The DCA axis was >3.5 indicating that ca-
nonical correspondence analysis (CCA) was the most
appropriate ordination method). Direct ordination was
performed with Monte Carlo permutation testing (499
permutations) using CANOCO 4.5 [8]. Constrained (ca-
nonical) analyses show variation between the sample pro-
files that can be explained by the measured categorical
and continuous variables of interest e.g. FEV1% predicted
or gender (Table 1).
Subsequently, processed sequencing matrices were ana-
lysed using soft class modelling (PLS-DA) to investigate
trends in community composition and identify those taxa
from the 454 analyses that contribute most to community
variation.
Soft-Class modelling of pyrosequence data
Patient samples were classified according to two main pa-
rameters; the first, current clinical status at time of sam-
pling (exacerbating versus stable) and secondly, overall
12 month exacerbation history (frequent exacerbators; >3
events per annum (M1) versus infrequent exacerbators ≤3
event per annum (M2)). Assessment of overall community
composition and relationship between clinically important
pathogens namely Pseudomonadaceae (including Pseudo-
monas aeruginosa), Pasteurellaceae (including Haemophi-
lus influenzae), Streptococcaceae (including Streptococcus
pneumoniae), Enterobacteriaceae, (including Escheri-
chia coli, Serratia liquefaciens and Morganella morga-
nii), Xanthomonadaceae (including Stenotrophomonas
maltophilia) and members of the genera Veillonella, Pre-
votella, and Neisseria were explored. Data were analysed
using supervised discriminant analysis to explore the lin-
ear regression between the microbial community struc-
tures (X) and the defined descriptive variables (Y). Sputum
from patients reporting clinical stability at time of sam-
pling were used as matched controls against samples
taken from exacerbating patients.
Group classification was based on within patient sam-
pling through time, exacerbation frequency (>3 exacer-
bation events per annum), current clinical status (stable
Purcell et al. BMC Microbiology 2014, 14:130 Page 10 of 11
http://www.biomedcentral.com/1471-2180/14/130versus exacerbated) and presence of major pathogens to
assess the effects of these parameters on microbial com-
munity assemblage (SIMCA, Umetrics). To check that
data was adhering to multivariate normalities, Hotelling’s
T2 tolerance limits were calculated and set at 0.95. Out-
liers that were deemed to be moderate, and unable to
shift in the model plane were also subjected to a
DModX (Distance to model in the X space) calculation
to assess those outliers that did not fit the model well,
and deviate from the normal F-distribution (critical
distance 0.05).
Additional files
Additional file 1: Table S1. Clinical information on patient cohort.
Additional file 2: Figure S2. Family level bar plot of all samples that
underwent 454 pyrosequencing.
Additional file 3: Table S2. Analyses of pyrosequence data to species
level giving total number of reads, putative identification of each taxon
and their contribution expressed as percentage of total reads.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PP carried out the collection of the pyrosequencing and patient data,
contributed to the statistical analyses of these data sets and helped draft the
manuscript. HJ coordinated the collection of the patient specific data and
helped to draft the manuscript. AP undertook the culture based analyses of
samples. JDP participated in the study design, culture based analyses and
coordination and helped to draft the manuscript. CJS generated sequence
information and contributed to the statistical analysis. AN contributed to the
statistical analyses of these data sets and helped draft the manuscript. CL
participated in the design of the study and performed the statistical analysis.
DLS participated in the generation and analysis the sequence data. SPC
conceived of the study, and participated in its design and coordination and
drafted the manuscript. ADS conceived of the study, and participated in its
design and coordination and helped to draft the manuscript. All authors
read and approved the final manuscript.
Acknowledgements
PP, SPC, CJS,AN, CL, DLS HJ, AP, JDP, ADS were funded by Northumbria
University and by the Microbiology Department, Newcastle upon Tyne NHS
Foundation Trust, The Freeman Hospital, Freeman Road, High Heaton,
Newcastle upon Tyne, NE7 7DN. The funding bodies made no contributions
to design of the study, or in the collection, analysis, interpretation of data.
They did not contribute to the writing of the manuscript; or in the decision
to submit the manuscript for publication.
Author details
1Department of Applied Sciences, Ellison Building, University of Northumbria,
Newcastle upon Tyne NE1 8ST, England. 2Transplantation and
Immunobiology Group, Institute of Cellular Medicine, Newcastle University
NE2 4HH and Adult Bronchiectasis Unit Freeman Hospital, Newcastle upon
Tyne NE7 7DN, England. 3Department of Microbiology, Freeman Hospital,
Newcastle upon Tyne, UK. 4Adult Cystic Fibrosis Unit, Department of
Respiratory Medicine, Royal Victoria Hospital, Newcastle upon Tyne NE7 7DN,
England.
Received: 27 November 2013 Accepted: 12 May 2014
Published: 20 May 2014
References
1. King P: Pathogenesis of bronchiectasis. Paediatr Respir Rev 2011, 12:104–110.2. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden RA,
Flower CD, Bilton D, Keogan MT: An investigation into causative factors in
patients with bronchiectasis. Am J Respir Crit Care Med 2000, 162:1277–1284.
3. Wilson CB, Jones PW, O’Leary CJ, Hansell DM, Cole PJ, Wilson R: Effect of
sputum bacteriology on the quality of life of patients with
bronchiectasis. Eur Respir J 1997, 10:1754–1760.
4. Angrill J, Agusti C, de Celis R, Rañó A, Gonzalez J, Sole T, Xaubet A,
Rodriguez-Roisin R, Torres A: Bacterial colonisation in patients with
bronchiectasis: microbiological pattern and risk factors. Thorax 2002,
57:15–19.
5. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW: Microbiologic
follow-up study in adult bronchiectasis. Respir Med 2007, 101:1633–1638.
6. Davies G, Wells AU, Doffman S, Watanabe S, Wilson R: The effect of
Pseudomonas aeruginosa on pulmonary function in patients with
bronchiectasis. Eur Respir J 2006, 28:974–979.
7. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Román-Sánchez P,
Soriano J: Factors associated with lung function decline in adult patients
with stable non-cystic fibrosis bronchiectasis. Chest 2007, 132:1565–1572.
8. Nelson A, De-Soyza A, Perry JD, Sutcliffe IC, Cummings SP: Polymicrobial
challenges to Koch’s postulates: Ecological lessons from the bacterial
vaginosis and cystic fibrosis microbiomes. Innate Immun 2012, 18:774–783.
9. Tunney M, Einarsson G, Wei L, Drain M, Klem ER, Cardwell C, Ennis M,
Boucher RC, Wolfgang MC, Elborn JS: The lung microbiota and bacterial
abundance in patients with bronchiectasis when clinically stable and
during exacerbation. Am J Respir Crit Care Med 2013, 187:1118–1126.
10. Cox MJ, Allgaier M, Taylor B, Baek MS, Huang YJ, Daly RA, Karaoz U,
Andersen GL, Brown R, Fujimura KE, Wu B, Tran D, Koff J, Kleinhenz ME,
Nielson D, Brodie EL, Lynch SV: Airway microbiota and pathogen abundance
in age-stratified cystic fibrosis patients. PLoS One 2010, 5:e11044.
11. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK: Clinical measures
of disease in adult non-CF bronchiectasis correlate with airway microbiota
composition. Thorax 2013, 68:731–777.
12. Rogers GB, Carroll MP, Seriser DJ, Hockey PM, Jones G: Use of 16S rRNA
profiling by terminal restriction fragment length polymorphism analysis
to compare bacterial communities in sputum and mouthwash samples
from patients with cystic fibrosis. J Clin Microbiol 2006, 44:2601–2604.
13. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L,
Schmidt LA, Young VB, Toews GB, Curtis JL, Sundaram B, Martinez FJ,
Huffnagle GB: Analysis of the lung microbiome in the “healthy” smoker
and in COPD. PLoS One 2011, 6:e16384.
14. Van der Gast CJ, Walker AW, Stressmann FA, Rogers GB, Scott P, Daniels TW,
Carroll MP, Parkhill J, Bruce KD: Partitioning core and satellite taxa from
within cystic fibrosis lung bacterial communities. ISME J 2011, 5:780–791.
15. Tunney M, Klem ER, Fodor AA, Gilpin DF, Moriarty TF: Use of culture and
molecular analysis to determine the effect of antibiotic treatment on
microbial community diversity and abundance during exacerbation in
patients with cystic fibrosis. Thorax 2011, 66:579–584.
16. Grimwood K: Airway microbiology and host defences in paediatric non-CF
bronchiectasis. Paediatr Respir Rev 2011, 12:111–118.
17. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M,
Wilson R: Mortality in bronchiectasis: a long-term study assessing the
factors influencing survival. Eur Respir J 2009, 34:843–849.
18. Klepac-Ceraj V, Lemon KP, Martin TR, Allgaier M, Kembel SW: Relationship
between cystic fibrosis respiratory tract bacterial communities and age,
genotype, antibiotics and Pseudomonas aeruginosa. Environ Microbiol
2010, 12:1293–1303.
19. Riley TV, Hoffmann DC: Interference with Haemophilus influenzae growth
by other microorganisms. FEMS Microbiol Letts 1986, 33:55–58.
20. Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP,
Hoffman L, Daniels TWV, Patel N, Forbes B, Bruce KD: Long-term
cultivation-independent microbial diversity analysis demonstrates that
bacterial communities infecting the adult cystic fibrosis lung show stabil-
ity and resilience. Thorax 2012, 67:867–873.
21. Brown SP, Inglis RF, Taddei F: Evolutionary ecology of microbial wars:
within-host competition and (incidental) virulence. Evol Appl 2009, 2:32–39.
22. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG: A
polymicrobial perspective of pulmonary infections exposes an enigmatic
pathogen in cystic fibrosis patients. Proc Natl Acad Sci U S A 2008,
105:15070–15075.
23. Foweraker JE, Wat D: Microbiology of non-CF bronchiectasis. Eur Respir Soc
Mono 2011, 52:68–96.
Purcell et al. BMC Microbiology 2014, 14:130 Page 11 of 11
http://www.biomedcentral.com/1471-2180/14/13024. Weinreich UM, Korsgaard J: Bacterial colonisation of lower airways in
health and chronic lung disease. Clin Respir J 2008, 2:116–122.
25. Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TW: Does bacterial
density in cystic fibrosis sputum increase prior to pulmonary
exacerbation? J Cyst Fibros 2011, 10:357–365.
26. Anwar GA, Bourke SC, Afolabi G, Middleton P, Ward C, Rutherford RM:
Effects of long-term low-dose azithromycin in patients with non-CF
bronchiectasis. Respir Med 2008, 102:1494–1496.
27. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT: Short- and
long-term antibiotic treatment reduces airway and systemic inflammation
in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 1867,
2012:657–665.
28. Pasteur MC, Bilton D, Hill AT, British Thoracic Society Non-CF Bronchiectasis
Guideline Group: British Thoracic Society guideline for non-CF bronchiectasis.
Thorax 2010, 65:577.
29. van Veen SQ, Claas EC, Kuijper EJ: High-throughput identification of bacteria
and yeast by matrix-assisted laser desorption ionization-time of flight mass
spectrometry in conventional medical microbiology laboratories. J Clin
Microbiol 2010, 48:900–907.
30. Muyzer G, de Waal EC, Uitterlinden AG: Profiling of complex microbial
populations by denaturing gradient gel electrophoresis analysis of
polymerase chain reaction-amplified genes coding for 16S rRNA. Appl
Environ Microbiol 1993, 59:695–700.
31. Dowd SE, Sun Y, Secor PR, Rhoads DD, Wolcott BM, James GA, Wolcott RD:
Survey of bacterial diversity in chronic wounds using pyrosequencing,
DGGE, and full ribosome shotgun sequencing. BMC Microbiol 2008, 8:43.
32. Caporaso JG, Kuczynski J, Stombaugh J: QIIME allows analysis of
high-throughput community sequencing data. Nature 2010, 7:335–336.
33. Edgar RC: Search and clustering orders of magnitude faster than BLAST.
Bioinformatics 2010, 26:2460–2461.
34. Caporaso JG, Bittinger K: PyNAST: a flexible tool for aligning sequences to
a template alignment. Bioinformatics 2010, 26:266–267.
35. Wang Q, Garrity GM, Tiedje JM, Cole JR: Naive Bayesian classifier for rapid
assignment of rRNA sequences into the new bacterial taxonomy. Appl
Environ Microbiol 2007, 73:5261–5267.
36. Price MN, Dehal PS, Arkin AP: FastTree 2-approximately maximum-likelihood
trees for large alignments. PLoS One 2010, 5:e9490.
37. Lindstrom ES, Kamst-Van Agterveld MP, Zwart G: Distribution of typical
freshwater bacterial groups is associated with pH, temperature, and lake
water retention time. Appl Environ Microbiol 2005, 71:8201–8206.
doi:10.1186/1471-2180-14-130
Cite this article as: Purcell et al.: Polymicrobial airway bacterial
communities in adult bronchiectasis patients. BMC Microbiology
2014 14:130.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
